Medical Condition News

RSS

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

Unigene Laboratories, Inc. (http://www.unigene.com) announced today that it has selected a lead peptide compound, designated UGP281, from its obesity program for development.

18 Dec 2009

AST: Finding right autism treatment can greatly impact child's progress and future quality of life

Autism Spectrum Therapies (AST), an agency providing behavior therapy and other autism services throughout Southern California, offers practical tips for parents on selecting the best autism service provider for their child.

18 Dec 2009

Access to convenience stores can pormote childhood obesity

Childhood obesity is directly related to how close kids live to convenience stores, according to the preliminary findings of a major Canadian study presented at the Entretiens Jacques-Cartier in Lyon, France. The ongoing study is named QUALITY for Quebec Adipose and Lifestyle InvesTigation in Youth.

18 Dec 2009

Cannabis can cause depression and anxiety in teenagers

Canadian teenagers are among the largest consumers of cannabis worldwide. The damaging effects of this illicit drug on young brains are worse than originally thought, according to new research by Dr. Gabriella Gobbi, a psychiatric researcher from the Research Institute of the McGill University Health Centre. The new study, published in Neurobiology of Disease, suggests that daily consumption of cannabis in teens can cause depression and anxiety, and have an irreversible long-term effect on the brain.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

Landmark study provides new insight into congenital heart defects

Researchers from the UC San Diego, School of Medicine and colleagues have identified a new gene, ETS-1, that is linked to human congenital heart defects. The landmark study, recently published online in the journal of Human Molecular Genetics, provides important insights into some of the most prevalent forms of congenital heart defects in humans, including ventricular septal defects and potentially hypoplastic left heart syndrome, a uniformly fatal heart abnormality.

18 Dec 2009

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

18 Dec 2009

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Calorie-intake restriction can benefit longevity and help prevent cancer

Researchers from the University of Alabama at Birmingham (UAB) have discovered that restricting consumption of glucose, the most common dietary sugar, can extend the life of healthy human-lung cells and speed the death of precancerous human-lung cells, reducing cancer's spread and growth rate.

18 Dec 2009

Acute kidney injury associated with increased long-term mortality

Patients with sudden loss of kidney function, called acute kidney injury (AKI), are more likely to die prematurely after leaving the hospital—even if their kidney function has apparently recovered, according to an upcoming study inJournal of the American Society of Nephrology (JASN).

18 Dec 2009

Scientists discover new model to asses homeostatic relationships between body substances

The Center for Modeling Optimal Outcomes, LLC, a New Jersey based think tank focused on the application of neuroscience in business, inadvertently discovered a scientifically verifiable model for assessing homeostasis (balance) between substances in the body.

18 Dec 2009

Alternative therapy for hypertension

New research from the Northwestern University Feinberg School of Medicine has found that an alternative therapy may be possible for treating some types of hypertension using an enzyme called ACE2.

18 Dec 2009

Hydrocephalus Association awards stimulus grants for research initiative

The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.

17 Dec 2009

PRPS1 gene associated with DFN2 identified by researchers

A gene associated with a rare form of progressive deafness in males has been identified by an international team of researchers funded by the National Institute on Deafness and Other Communication Disorders.

17 Dec 2009

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

17 Dec 2009

Switching between A-rated anti-epileptic drug formulations does not increase seizure risk

Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, announced today results of a study that examined the association of seizure risk among epilepsy patients after switching between A-rated anti-epileptic drug formulations. The study found no evidence that switching between A-rated anti-epileptic drugs, including brand to generic substitution, was associated with increased emergency room visits or hospitalizations for epilepsy.

17 Dec 2009

Interleukin Genetics introduces the Bone Health Genetic Test

Interleukin Genetics, Inc. announced today availability of the Bone Health Genetic Test designed to detect genetic patterns associated with the development of osteoporosis-related outcomes. The test determines an individual's risk for developing vertebral or spinal fractures and low bone mineral density.

17 Dec 2009

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Revolutions Medical Corporation, producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

Medical Condition News

Unigene Laboratories selects UGP281 lead peptide from obesity program for development

AST: Finding right autism treatment can greatly impact child's progress and future quality of life

Access to convenience stores can pormote childhood obesity

Cannabis can cause depression and anxiety in teenagers

Phase 2 clinical study of STA-9090 in NSCLC initiated

Landmark study provides new insight into congenital heart defects

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Calorie-intake restriction can benefit longevity and help prevent cancer

Acute kidney injury associated with increased long-term mortality

Scientists discover new model to asses homeostatic relationships between body substances

Alternative therapy for hypertension

Hydrocephalus Association awards stimulus grants for research initiative

PRPS1 gene associated with DFN2 identified by researchers

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Switching between A-rated anti-epileptic drug formulations does not increase seizure risk

Interleukin Genetics introduces the Bone Health Genetic Test

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News